Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies

BACKGROUND: Patients with anaplastic lymphoma kinase rearranged (ALK+) non-small cell lung cancer (NSCLC) have a higher risk of developing brain metastases (BMs) than patients with other NSCLC sub-types. ALK inhibitors have activity in BMs due to ALK+ NSCLC. We performed a systematic review of the l...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrelli, Fausto, Lazzari, Chiara, Ardito, Raffaele, Borgonovo, Karen, Bulotta, Alessandra, Conti, Barbara, Cabiddu, Mary, Capitanio, Jody Filippo, Brighenti, Matteo, Ghilardi, Mara, Gianni, Luca, Barni, Sandro, Gregorc, Vanesa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063430/
https://www.ncbi.nlm.nih.gov/pubmed/30052658
http://dx.doi.org/10.1371/journal.pone.0201425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063430/
https://www.ncbi.nlm.nih.gov/pubmed/30052658
http://dx.doi.org/10.1371/journal.pone.0201425

Ejemplares similares